Eintrag weiter verarbeiten
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
Gespeichert in:
| Zeitschriftentitel: | JNCI Cancer Spectrum |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , |
| In: | JNCI Cancer Spectrum, 5, 2021, 1 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L |
|---|---|
| author |
Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L |
| spellingShingle |
Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L JNCI Cancer Spectrum Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis Cancer Research Oncology |
| author_sort |
iafolla, marco a j |
| spelling |
Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L 2515-5091 Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1093/jncics/pkaa115 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA haplotype dimorphism at positions −21 M and −21 T of the HLA-A and -B leader sequence were analyzed as predictors of toxicity defined as grade 2 or greater immune-related adverse events and clinical benefit defined as complete or partial response, or stable disease for 6 or more cycles of pembrolizumab. Statistical significance tests were 2-sided.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In the overall cohort of 101 patients, the frequency of toxicity and clinical benefit from pembrolizumab was 22.8% and 25.7%, respectively. There was no association between any of the HLA-1 loci or alleles with toxicity. HLA-C heterozygosity had an association with decreased clinical benefit relative to HLA-C homozygosity when controlling for cohort (odds ratio = 0.28, 95% confidence interval = 0.09 to 0.91, P = .04). HLA-A and -B haplotype −21 M/T dimorphism and heterozygosity of HLA-A, -B, and -C were not predictive of outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>HLA-C heterozygosity may predict decreased response to pembrolizumab. Prospective validation is required.</jats:p> </jats:sec> Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis JNCI Cancer Spectrum |
| doi_str_mv |
10.1093/jncics/pkaa115 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qbmNpY3MvcGthYTExNQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qbmNpY3MvcGthYTExNQ |
| institution |
DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Oxford University Press (OUP), 2021 |
| imprint_str_mv |
Oxford University Press (OUP), 2021 |
| issn |
2515-5091 |
| issn_str_mv |
2515-5091 |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
iafolla2021predictingtoxicityandresponsetopembrolizumabthroughgermlinegenomichlaclass1analysis |
| publishDateSort |
2021 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
JNCI Cancer Spectrum |
| source_id |
49 |
| title |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_unstemmed |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_full |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_fullStr |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_full_unstemmed |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_short |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_sort |
predicting toxicity and response to pembrolizumab through germline genomic hla class 1 analysis |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1093/jncics/pkaa115 |
| publishDate |
2021 |
| physical |
|
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA haplotype dimorphism at positions −21 M and −21 T of the HLA-A and -B leader sequence were analyzed as predictors of toxicity defined as grade 2 or greater immune-related adverse events and clinical benefit defined as complete or partial response, or stable disease for 6 or more cycles of pembrolizumab. Statistical significance tests were 2-sided.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>In the overall cohort of 101 patients, the frequency of toxicity and clinical benefit from pembrolizumab was 22.8% and 25.7%, respectively. There was no association between any of the HLA-1 loci or alleles with toxicity. HLA-C heterozygosity had an association with decreased clinical benefit relative to HLA-C homozygosity when controlling for cohort (odds ratio = 0.28, 95% confidence interval = 0.09 to 0.91, P = .04). HLA-A and -B haplotype −21 M/T dimorphism and heterozygosity of HLA-A, -B, and -C were not predictive of outcomes.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>HLA-C heterozygosity may predict decreased response to pembrolizumab. Prospective validation is required.</jats:p>
</jats:sec> |
| container_issue |
1 |
| container_start_page |
0 |
| container_title |
JNCI Cancer Spectrum |
| container_volume |
5 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344407388717061 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:07:01.822Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Predicting+Toxicity+and+Response+to+Pembrolizumab+Through+Germline+Genomic+HLA+Class+1+Analysis&rft.date=2021-01-05&genre=article&issn=2515-5091&volume=5&issue=1&jtitle=JNCI+Cancer+Spectrum&atitle=Predicting+Toxicity+and+Response+to+Pembrolizumab+Through+Germline+Genomic+HLA+Class+1+Analysis&aulast=Siu&aufirst=Lillian+L&rft_id=info%3Adoi%2F10.1093%2Fjncics%2Fpkaa115&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344407388717061 |
| author | Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L |
| author_facet | Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L, Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L |
| author_sort | iafolla, marco a j |
| container_issue | 1 |
| container_start_page | 0 |
| container_title | JNCI Cancer Spectrum |
| container_volume | 5 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA haplotype dimorphism at positions −21 M and −21 T of the HLA-A and -B leader sequence were analyzed as predictors of toxicity defined as grade 2 or greater immune-related adverse events and clinical benefit defined as complete or partial response, or stable disease for 6 or more cycles of pembrolizumab. Statistical significance tests were 2-sided.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In the overall cohort of 101 patients, the frequency of toxicity and clinical benefit from pembrolizumab was 22.8% and 25.7%, respectively. There was no association between any of the HLA-1 loci or alleles with toxicity. HLA-C heterozygosity had an association with decreased clinical benefit relative to HLA-C homozygosity when controlling for cohort (odds ratio = 0.28, 95% confidence interval = 0.09 to 0.91, P = .04). HLA-A and -B haplotype −21 M/T dimorphism and heterozygosity of HLA-A, -B, and -C were not predictive of outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>HLA-C heterozygosity may predict decreased response to pembrolizumab. Prospective validation is required.</jats:p> </jats:sec> |
| doi_str_mv | 10.1093/jncics/pkaa115 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9qbmNpY3MvcGthYTExNQ |
| imprint | Oxford University Press (OUP), 2021 |
| imprint_str_mv | Oxford University Press (OUP), 2021 |
| institution | DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2515-5091 |
| issn_str_mv | 2515-5091 |
| language | English |
| last_indexed | 2024-03-01T17:07:01.822Z |
| match_str | iafolla2021predictingtoxicityandresponsetopembrolizumabthroughgermlinegenomichlaclass1analysis |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | JNCI Cancer Spectrum |
| source_id | 49 |
| spelling | Iafolla, Marco A J Yang, Cindy Chandran, Vinod Pintilie, Melania Li, Quan Bedard, Philippe L Hansen, Aaron Lheureux, Stephanie Spreafico, Anna Razak, Albiruni A Hakgor, Sevan Giesler, Amanda Pugh, Trevor J Siu, Lillian L 2515-5091 Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1093/jncics/pkaa115 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted from whole-exome sequencing using HLAminer and HLAVBSeq. Heterozygosity of HLA-A, -B, and -C, individual HLA-1 alleles, and HLA haplotype dimorphism at positions −21 M and −21 T of the HLA-A and -B leader sequence were analyzed as predictors of toxicity defined as grade 2 or greater immune-related adverse events and clinical benefit defined as complete or partial response, or stable disease for 6 or more cycles of pembrolizumab. Statistical significance tests were 2-sided.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In the overall cohort of 101 patients, the frequency of toxicity and clinical benefit from pembrolizumab was 22.8% and 25.7%, respectively. There was no association between any of the HLA-1 loci or alleles with toxicity. HLA-C heterozygosity had an association with decreased clinical benefit relative to HLA-C homozygosity when controlling for cohort (odds ratio = 0.28, 95% confidence interval = 0.09 to 0.91, P = .04). HLA-A and -B haplotype −21 M/T dimorphism and heterozygosity of HLA-A, -B, and -C were not predictive of outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>HLA-C heterozygosity may predict decreased response to pembrolizumab. Prospective validation is required.</jats:p> </jats:sec> Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis JNCI Cancer Spectrum |
| spellingShingle | Iafolla, Marco A J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J, Siu, Lillian L, JNCI Cancer Spectrum, Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis, Cancer Research, Oncology |
| title | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_full | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_fullStr | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_full_unstemmed | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_short | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| title_sort | predicting toxicity and response to pembrolizumab through germline genomic hla class 1 analysis |
| title_unstemmed | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1093/jncics/pkaa115 |